Please assess the completion status of the following clinical trial:

Trial Title: Monoclonal Antibody Therapy in Treating Patients Scheduled for Surgery to Remove Ovarian Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~Cytologic or pathologic diagnosis consistent with ovarian carcinoma. Scheduled to undergo surgical evaluation. Karnofsky performance status of \> 60%.~Adequate organ function as defined by:~* Absolute neutrophil count (ANC) \> 1.5 x 10\^9/L~* Platelet count \> 100 x 10\^9/L~* Bilirubin \< 2.0 mg/dL~* Aspartate aminotransferase (AST) and Alanine transaminase (ALT) \< 2.5 X upper limit of normal~* Serum creatinine \< 2.0 mg/dL~* Forced expiratory volume at one second (FEV1) and forced vital capacity (FVC)\> 70% of predicted~* Left Ventricular Ejection Fraction \>50%~Recovered from the toxicity of any prior therapy. No evidence of active infection which requires antibiotic therapy. \> 18 years of age. Able to sign written informed consent.~Exclusion Criteria~Any significant intercurrent medical problems which may limit the amount of antibody they can tolerate, or render them ineligible for surgery.~Clinically significant cardiac disease (New York Heart Association Class III/IV, or abnormalities on ECG that are considered by the investigator to place the patient at increased risk), severe debilitating pulmonary disease, active infections or coagulation disorders.~Survival expectancy less than 12 weeks. History of autoimmune hepatitis or history of autoimmune disease. Chemotherapy, radiotherapy, or immunotherapy within four weeks prior to receiving hu3S193.~Psychiatric, addictive or other disorders that compromise the ability to give informed consent.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intraperitoneal (IP) Infusion of 111In-hu3S193 (Type: EXPERIMENTAL): Hu3S193 was administered intraperitoneally at a dose of 5 mg radiolabeled with 5 millicurie (mCi) of 111In.~Patients received 10 mCi 99mTc-sulphur colloid IP administered in 500 ml of normal saline to assure the absence of any loculation or heterogeneous distribution of radioactivity in the peritoneal cavity. A paracentesis catheter was inserted and the hu3S193 was diluted in 100 mL of 5% human serum albumin and administered as a continuous intraperitoneal infusion over 30 minutes. This was followed immediately by 900 mL of normal saline.
- Intravenous Infusion of 111In-hu3S193 (Type: EXPERIMENTAL): Hu3S193 was to be administered intravenously at a dose of 5 mg radiolabeled with 5 millicurie (mCi) of 111In, diluted in 100 mL of 5% human serum albumin and administered over a 30 minute period.

Based on this trial design, predict the completion outcome and termination type (if applicable).